Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients

Background Treatment of HIV infection in adolescents is challenging due to long duration of therapy and poor adherence. Recently, the integrase strand transfer inhibitor dolutegravir (DTG) has been approved for the use in adolescents with HIV, but evidence in clinical practice is very limited.